English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Biologics development represents a substantial advancement in the pharmaceutical industry because of their promise and huge success in the oncology, immunoscience, and cardiovascular disease areas. Prior to entering the marketed product development phase, each biopharmaceutical needs to go through series of stages that will allow or disallow the biologics asset to become a commercialized product. Each of those phases includes development planning and designing of studies to test relevant hypotheses to support the drug label if approved. In this study, the findings from the survey that was conducted previously as planned. It is organized into various sections, which include a summary of the study approach, the original research questions and hypotheses, the actual number of interviewed participants and response rate, and the general quantitative results of the survey in terms of gender, age, department, and experience. The chapter then presents qualitative results from content analysis and then finally, an in-depth discussion of the implication of these findings.

Survey Based Study to Assess the Principles, Assumptions, and Processes in Establishing Biologics Assets as a Fast to FIH (First-In-Human)